Filing Flows › Theravance Biopharma (TBPH) › Q1 2026
Theravance Biopharma (TBPH) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Theravance Biopharma (TBPH) reported revenue of $17.7M for the first quarter 2026 (Q1 2026), +15% from a year earlier and -61% from the quarter before. Operating margin was -53.6%, net loss $4.9M (27.9% of revenue).
Theravance Biopharma, Q1 2026: revenue $17.7M (+15% year over year), operating margin -53.6%, net loss $4.9M, operating cash flow $73.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.7M | -61% | +15% |
| Operating profit | −$9.5M | -147% | — |
| Net earnings | −$4.9M | -108% | — |
| Operating cash flow | $73.3M | — | +70% |
What changed
Revenue was $17.7M in Q1 2026, up 15% year over year and down 61% from the previous quarter.
Operating costs exceeded revenue by $9.5M, an operating margin of -53.6%. Total costs fell 9% while revenue rose 15%. The quarter ended with a net loss of $4.9M, after a profit of $61.0M the previous quarter. Non-operating items added $3.0M, -47% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $73.3M (up 70% year over year). Non-cash charges added back $4.5M of share-based compensation. Working capital and other items added $73.7M.
Questions
What was Theravance Biopharma's revenue in the first quarter 2026?
Theravance Biopharma (TBPH) reported revenue of $17.7M for the first quarter 2026 (Q1 2026), +15% from a year earlier and -61% from the quarter before.
Was Theravance Biopharma profitable in the first quarter 2026?
Operating loss was $9.5M (-53.6% of revenue) and net loss $4.9M.